The Azora acquisition and $32M financing reset Adial's pipeline to a preclinical-stage UC asset with no near-term revenue. Monitor IND filing progress in H1 2027 and any milestone-triggered second $32M tranche. The $46.2M non-cash charge is accounting noise; the key metric is cash runway into H2 2027.
Price Chart
Executive Summary
Adial Pharmaceuticals reported Q2 2026 results with a net loss of $52.0M ($11.25 per share), driven by a $46.2M non-cash charge for acquired in-process R&D from the Azora Therapeutics acquisition. The company completed the first $32M tranche of a $64M private placement, ending the quarter with $28.7M cash, and shifted its strategic focus to AT177, an oral AhR agonist for ulcerative colitis, with an IND filing planned for H1 2027. The large non-cash loss and early-stage pipeline make this a neutral event with no immediate revenue or earnings catalyst.
Key Financial Metrics
Key Facts
- Net loss of $52.0M for Q2 2026, or $(11.25) per share, vs. $2.0M loss ($4.61 per share) in Q2 2025
- Acquired Azora Therapeutics, adding AT177 (oral AhR agonist for ulcerative colitis) to pipeline
- Closed first $32M tranche of up to $64M private placement, including conversion of $5.5M notes
- Cash and equivalents $28.7M as of June 30, 2026, up from $4.6M at March 31, 2026
- IND filing for AT177 planned for H1 2027; Phase 1a SAD/MAD trial expected H2 2027
- Acquired in-process R&D expense of $46.2M (non-cash) drove the large net loss
Financial Impact
Net loss of $52.0M driven by $46.2M non-cash IPR&D charge; cash position $28.7M
Risk Factors
- Preclinical-stage pipeline with no approved products or revenue
- Stockholders' deficit of $38.4M and Series A convertible preferred stock pending stockholder approval
- Potential dilution from conversion of Series A preferred (12.9M additional shares) and milestone warrants
- Nasdaq listing risk if conditional approval not obtained
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345948 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.77 (+8.39%) |
Oct 20, 2026 5d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.77 (+8.39%) |
Oct 16, 2026 9d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.77 (−4.01%) |
Oct 16, 2026 9d ago | 8-K | $3.62 | awaiting T+60 | — | $3.77 (−4.01%) |
Sep 30, 2026 25d ago | Press Release | $4.13 | awaiting T+60 | — | $3.77 (−8.84%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.77 (−14.43%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.77 (−14.43%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.77 (−27.74%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.77 (−27.74%) |
Aug 17, 2026 10w ago | 8-K | $4.99 | awaiting T+60 | — | $3.77 (−24.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers